File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters

TitleRecurrent TET2 mutations in peripheral T-cell lymphomas correlate with T<inf>FH</inf>-like features and adverse clinical parameters
Authors
Issue Date2012
Citation
Blood, 2012, v. 120, n. 7, p. 1466-1469 How to Cite?
AbstractInactivating mutations of the Ten-Eleven Translocation 2 (TET2) gene were first identified in myeloid malignancies and more recently in peripheral T-cell lymphomas (PTCLs). In the present study, we investigated the presence of TET2 coding sequence mutations and their clinical relevance in a large cohort of 190 PTCL patients. TET2 mutations were identified in 40 of 86 (47%) cases of angioimmunoblastic T-cell lymphoma (AITL) and in 22 of 58 (38%) cases of peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), but were absent in all other PTCL entities, with the exception of 2 of 10 cases of enteropathy-associated T-cell lymphoma. Among PTCL-NOS, a heterogeneous group of lymphoma-comprising cases likely to derive from Th follicular (T FH) cells similarly to AITL, TET2 mutations were more frequent when PTCL-NOS expressed T FH markers and/or had features reminiscent of AITL (58% vs 24%, P = .01). In the AITL and PTCL-NOS subgroups, TET2 mutations were associated with advanced-stage disease, thrombocytopenia, high International Prognostic Index scores, and a shorter progression-free survival. © 2012 by The American Society of Hematology.
Persistent Identifierhttp://hdl.handle.net/10722/292720
ISSN
2023 Impact Factor: 21.0
2023 SCImago Journal Rankings: 5.272
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLemonnier, François-
dc.contributor.authorCouronné, Lucile-
dc.contributor.authorParrens, Marie-
dc.contributor.authorJaïs, Jean Philippe-
dc.contributor.authorTravert, Marion-
dc.contributor.authorLamant, Laurence-
dc.contributor.authorTournillac, Olivier-
dc.contributor.authorRousset, Therese-
dc.contributor.authorFabiani, Bettina-
dc.contributor.authorCairns, Rob A.-
dc.contributor.authorMak, Tak-
dc.contributor.authorBastard, Christian-
dc.contributor.authorBernard, Olivier A.-
dc.contributor.authorDe Leval, Laurence-
dc.contributor.authorGaulard, Philippe-
dc.date.accessioned2020-11-17T14:57:04Z-
dc.date.available2020-11-17T14:57:04Z-
dc.date.issued2012-
dc.identifier.citationBlood, 2012, v. 120, n. 7, p. 1466-1469-
dc.identifier.issn0006-4971-
dc.identifier.urihttp://hdl.handle.net/10722/292720-
dc.description.abstractInactivating mutations of the Ten-Eleven Translocation 2 (TET2) gene were first identified in myeloid malignancies and more recently in peripheral T-cell lymphomas (PTCLs). In the present study, we investigated the presence of TET2 coding sequence mutations and their clinical relevance in a large cohort of 190 PTCL patients. TET2 mutations were identified in 40 of 86 (47%) cases of angioimmunoblastic T-cell lymphoma (AITL) and in 22 of 58 (38%) cases of peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), but were absent in all other PTCL entities, with the exception of 2 of 10 cases of enteropathy-associated T-cell lymphoma. Among PTCL-NOS, a heterogeneous group of lymphoma-comprising cases likely to derive from Th follicular (T FH) cells similarly to AITL, TET2 mutations were more frequent when PTCL-NOS expressed T FH markers and/or had features reminiscent of AITL (58% vs 24%, P = .01). In the AITL and PTCL-NOS subgroups, TET2 mutations were associated with advanced-stage disease, thrombocytopenia, high International Prognostic Index scores, and a shorter progression-free survival. © 2012 by The American Society of Hematology.-
dc.languageeng-
dc.relation.ispartofBlood-
dc.titleRecurrent TET2 mutations in peripheral T-cell lymphomas correlate with T<inf>FH</inf>-like features and adverse clinical parameters-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1182/blood-2012-02-408542-
dc.identifier.pmid22760778-
dc.identifier.scopuseid_2-s2.0-84865197558-
dc.identifier.volume120-
dc.identifier.issue7-
dc.identifier.spage1466-
dc.identifier.epage1469-
dc.identifier.eissn1528-0020-
dc.identifier.isiWOS:000309001900019-
dc.identifier.issnl0006-4971-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats